Sam Slutsky
Stock Analyst at LifeSci Capital
(4.99)
# 38
Out of 4,662 analysts
641
Total ratings
56.8%
Success rate
52.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sam Slutsky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QNCX Quince Therapeutics | Maintained: Buy | $99 → $98 | $34.57 | +183.48% | 3 | Aug 19, 2026 | |
| OBX Obsidian Therapeutics | Initiated Coverage: Buy | $43 | $20.00 | +115.00% | 1 | Aug 18, 2026 | |
| ORKA Oruka Therapeutics | Maintained: Buy | $175 | $109.69 | +59.54% | 23 | Aug 15, 2026 | |
| SYRE Spyre Therapeutics | Maintained: Buy | $129 | $108.92 | +18.44% | 56 | Aug 15, 2026 | |
| PYXS Pyxis Oncology | Maintained: Buy | $6 | $3.37 | +78.04% | 21 | Aug 14, 2026 | |
| AVBP ArriVent BioPharma | Maintained: Buy | $42 → $43 | $30.02 | +43.24% | 27 | Aug 13, 2026 | |
| IMUX Immunic | Maintained: Buy | $56 | $16.45 | +240.43% | 5 | Aug 12, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Maintained: Buy | $22.24 | $9.72 | +128.78% | 10 | Aug 12, 2026 | |
| DMRA Damora Therapeutics | Maintained: Buy | $45 | $32.44 | +38.72% | 8 | Aug 11, 2026 | |
| OLMA Olema Pharmaceuticals | Maintained: Buy | $24 | $11.31 | +112.20% | 44 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $55 | $36.85 | +49.25% | 51 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $60 → $70 | $59.39 | +17.86% | 38 | Aug 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $56 | $41.70 | +34.29% | 43 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $53 | $44.96 | +17.88% | 72 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $108 | $80.68 | +33.86% | 34 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $2.12 | +135.85% | 33 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $2.06 | - | 29 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $225 → $236 | $149.96 | +57.38% | 25 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 | $4.08 | +292.16% | 14 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $0.75 | +700.00% | 22 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $46 → $45 | $14.78 | +204.47% | 13 | Jul 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $170 | $120.56 | +41.01% | 35 | Jun 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.16 | $0.9072 | n/a | 11 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $7.15 | n/a | 23 | Aug 9, 2023 |
Quince Therapeutics
Aug 19, 2026
Maintained: Buy
Price Target: $99 → $98
Current: $34.57
Upside: +183.48%
Obsidian Therapeutics
Aug 18, 2026
Initiated Coverage: Buy
Price Target: $43
Current: $20.00
Upside: +115.00%
Oruka Therapeutics
Aug 15, 2026
Maintained: Buy
Price Target: $175
Current: $109.69
Upside: +59.54%
Spyre Therapeutics
Aug 15, 2026
Maintained: Buy
Price Target: $129
Current: $108.92
Upside: +18.44%
Pyxis Oncology
Aug 14, 2026
Maintained: Buy
Price Target: $6
Current: $3.37
Upside: +78.04%
ArriVent BioPharma
Aug 13, 2026
Maintained: Buy
Price Target: $42 → $43
Current: $30.02
Upside: +43.24%
Immunic
Aug 12, 2026
Maintained: Buy
Price Target: $56
Current: $16.45
Upside: +240.43%
Eupraxia Pharmaceuticals Inc.
Aug 12, 2026
Maintained: Buy
Price Target: $22.24
Current: $9.72
Upside: +128.78%
Damora Therapeutics
Aug 11, 2026
Maintained: Buy
Price Target: $45
Current: $32.44
Upside: +38.72%
Olema Pharmaceuticals
Aug 11, 2026
Maintained: Buy
Price Target: $24
Current: $11.31
Upside: +112.20%
Aug 10, 2026
Maintained: Buy
Price Target: $55
Current: $36.85
Upside: +49.25%
Aug 8, 2026
Rated: Buy
Price Target: $60 → $70
Current: $59.39
Upside: +17.86%
Aug 7, 2026
Maintained: Buy
Price Target: $56
Current: $41.70
Upside: +34.29%
Aug 7, 2026
Maintained: Buy
Price Target: $53
Current: $44.96
Upside: +17.88%
Aug 7, 2026
Maintained: Buy
Price Target: $108
Current: $80.68
Upside: +33.86%
Aug 6, 2026
Maintained: Buy
Price Target: $5
Current: $2.12
Upside: +135.85%
Aug 6, 2026
Maintained: Hold
Price Target: n/a
Current: $2.06
Upside: -
Aug 5, 2026
Maintained: Buy
Price Target: $225 → $236
Current: $149.96
Upside: +57.38%
Aug 5, 2026
Maintained: Buy
Price Target: $16
Current: $4.08
Upside: +292.16%
Jul 29, 2026
Maintained: Buy
Price Target: $6
Current: $0.75
Upside: +700.00%
Jul 17, 2026
Rated: Buy
Price Target: $46 → $45
Current: $14.78
Upside: +204.47%
Jun 30, 2026
Maintained: Buy
Price Target: $170
Current: $120.56
Upside: +41.01%
Dec 14, 2023
Maintained: Hold
Price Target: $1.16
Current: $0.9072
Upside: n/a
Aug 9, 2023
Rated: Hold
Price Target: n/a
Current: $7.15
Upside: n/a